相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 技术资料
- 保存条件:
Powder: -20°C, 3 years; 4°C, 2 years.In solvent: -80°C, 6 months; -20°C, 1 month.
- 库存:
货期:1-2天
- 供应商:
MedChemExpress LLC
- CAS号:
147536-97-8
- 规格:
10 mM * 1 mL/50 mg/100 mg/200 mg/500 mg
| 规格: | 10 mM * 1 mL | 产品价格: | ¥660.0 |
|---|---|---|---|
| 规格: | 50 mg | 产品价格: | ¥600.0 |
| 规格: | 100 mg | 产品价格: | ¥1050.0 |
| 规格: | 200 mg | 产品价格: | ¥2000.0 |
| 规格: | 500 mg | 产品价格: | ¥3078.0 |
MCE 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务。
Bosentan
CAS No. : 147536-97-8
MCE 国际站:Bosentan
产品活性:Bosentan 是一种有效的 endothelin-1 (ET) 拮抗剂,在人的 SMC 细胞中,作用于 ETA 和 ETB 受体,Ki 值分别为 4.7 nM 和 95 nM。
研究领域:GPCR/G Protein
作用靶点:Endothelin Receptor
In Vitro: Bosentan (BOS) competitively and specifically antagonizes binding of 125I-labelled ET-1 to ETA receptors on human smooth muscle cells (SMC) and ETB receptors on human placenta cells. The in vitro binding affinity of Bosentan to ETA receptors on human SMC is 4.7 nM and to ETB receptors on human SMC or placenta cells is 41 or 95 nM. Bosentan has 67-fold greater selectivity for ETA than ETB receptors (mean IC50=7.1 vs 474.8 nM) in an in vitro 125I-labeling assay.
In Vivo: In hypertensive rats, Macitentan 30 mg/kg further decreases mean arterial blood pressure (MAP) by 19 mm Hg when given on top of Bosentan 100 mg/kg. Conversely, Bosentan given on top of Macitentan fails to induce an additional MAP decrease. In pulmonary hypertensive rats, Macitentan 30 mg/kg further decreases mean pulmonary artery pressure (MPAP) by 4 mm Hg on top of Bosentan, whereas a maximal effective dose of Bosentan given on top of Macitentan does not cause any additional MPAP decrease.
相关产品:Drug Repurposing Compound Library Plus | FDA-Approved Drug Library Plus | FDA-Approved Drug Library Mini | Bioactive Compound Library Plus | GPCR/G Protein Compound Library | FDA-Approved Drug Library | Anti-Cancer Compound Library | Drug Repurposing Compound Library | Anti-diabetic Compound Library | Anti-Cardiovascular Disease Compound Library | Endocrinology Compound Library | Anti-COVID-19 Compound Library | NMPA-Approved Drug Library | Orally Active Compound Library | Neurotransmitter Receptor Compound Library | FDA Approved & Pharmacopeial Drug Library | Drug-Induced Liver Injury (DILI) Compound Library | Anti-Pancreatic Cancer Compound Library | Angiogenesis-Related Compound Library | Rare Diseases Drug Library | Children’s Drug Library | EMA-Approved Drug Library | FDA-Approved Anticancer Drug Library | Human Metabolite Library | Anti-Pulmonary Fibrosis Compound Library | Coagulation and Anti-coagulation Compound Library | Pain-Related Compound Library | Off-patent Drug Library | Antihypertensive Compound Library | Membrane Protein-targeted Compound Library | Membrane Receptor-targeted Compound Library | Mitochondrial Toxicity Compound Library | Endothelin 1 (swine, human) | Macitentan | Ambrisentan | Atrasentan hydrochloride | BQ-123 | Bosentan hydrate | BQ-788 | Carperitide acetate | Atrial Natriuretic Peptide (ANP) (1-28), rat | Sulfisoxazole | Endothelin-3, human, mouse, rabbit, rat TFA | Sparsentan | Zibotentan | A-192621 | Sitaxsentan sodium | IRL-1620 TFA | Clazosentan | Nebentan potassium | Avosentan | Aprocitentan | Tezosentan | Darusentan | IRL 2500
热门产品线:重组蛋白 | 化合物库 | 天然产物 | 荧光染料 | PROTAC | 同位素标记物
Trending products:Recombinant Proteins | Bioactive Screening Libraries | Natural Products | Dye Reagents | PROTAC | Isotope-Labeled Compounds
风险提示:丁香通仅作为第三方平台,为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全,合理判断,谨慎选购商品,商家和用户对交易行为负责。对于医疗器械类产品,请先查证核实企业经营资质和医疗器械产品注册证情况。
技术资料暂无技术资料 索取技术资料

















